{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:28:10Z","timestamp":1771036090287,"version":"3.50.1"},"reference-count":129,"publisher":"Bentham Science Publishers Ltd.","issue":"16","funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province of China","doi-asserted-by":"publisher","award":["BK20130495"],"award-info":[{"award-number":["BK20130495"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81402840"],"award-info":[{"award-number":["81402840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Provincial Natural Science Foundation of China","doi-asserted-by":"publisher","award":["LY14H310010"],"award-info":[{"award-number":["LY14H310010"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2018YFA0108400"],"award-info":[{"award-number":["2018YFA0108400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2019,11,13]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Hepatitis B is a very harmful and epidemic disease caused by hepatitis B virus (HBV). Although an effective anti-HBV vaccine is available, chronic infection poses still a huge health burden in the whole world. The present anti-HBV drugs including nucleoside analogues and interferonalpha have their limitations without exception. There is no effective drug and therapeutic method that can really and truly cure hepatitis B so far. The variability of HBV genome results in that a significant number of patients develop drug resistance during the long-term use of anti-HBV drugs. Hence, it is urgently needed to discover novel targets and develop new drugs against hepatitis B.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>The review aims to provide the theory support for designing of the anti-HBV innovative drugs by offering a summary of the current situation of antiviral potential targets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and Conclusion:<\/jats:title><jats:p>Since HBV is obligate intracellular parasite, and as such it depends on host cellular components and functions to replicate itself. The targeting both virus and host might be a novel therapeutic option for hepatitis B. Accordingly, we analyse the advances in the study of the potential drug targets for anti-HBV infection, focusing on targeting virus genome, on targeting host cellular functions and on targeting virus-host proteins interactions, respectively. Meanwhile, the immune targets against chronic hepatitis B are also emphasized. In short, the review provides a summary of antiviral therapeutic strategies to target virus factors, host factors and immune factors for future designing of the innovative drug against HBV infection.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450120666190729115646","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T10:55:03Z","timestamp":1564484103000},"page":"1636-1651","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors"],"prefix":"10.2174","volume":"20","author":[{"given":"Bing-Yi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan-Ping","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4992-3052","authenticated-orcid":true,"given":"Yi-Hang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Peng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Institute of Life Sciences, Jiangsu University, Zhenjiang 212013, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Yong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Hong","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ping","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial Key Laboratory of Biometrology and Inspection & Quarantine, College of Life Sciences, China Jiliang University, Hangzhou 310018, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-virology-110615-042238","volume":"3","author":"Venkatakrishnan B.","year":"2016","unstructured":"Venkatakrishnan B.; Zlotnick A.; The structural biology of hepatitis B virus: form and function. Annu Rev Virol 2016,3(1),429-451","journal-title":"Annu Rev Virol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"Tr\u00e9po C.","year":"2014","unstructured":"Tr\u00e9po C.; Chan H.L.; Lok A.; Hepatitis B virus infection. Lancet 2014,384(9959),2053-2063","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"Schweitzer A.","year":"2015","unstructured":"Schweitzer A.; Horn J.; Mikolajczyk R.T.; Krause G.; Ott J.J.; Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015,386(10003),1546-1555","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S1473-3099(16)30214-6","volume":"16","author":"Wong G.L.","year":"2016","unstructured":"Wong G.L.; Wong V.W.; Eliminating hepatitis B virus as a global health threat. Lancet Infect Dis 2016,16(12),1313-1314","journal-title":"Lancet Infect Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/S1473-3099(15)00436-3","volume":"16","author":"Brahmania M.","year":"2016","unstructured":"Brahmania M.; Feld J.; Arif A.; Janssen H.L.; New therapeutic agents for chronic hepatitis B. Lancet Infect Dis 2016,16(2),e10-e21","journal-title":"Lancet Infect Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.bbrc.2006.03.204","volume":"344","author":"Yang J.","year":"2006","unstructured":"Yang J.; Ding X.; Zhang Y.; Bo X.; Zhang M.; Wang S.; Fibronectin is essential for hepatitis B virus propagation in vitro: may be a potential cellular target? Biochem Biophys Res Commun 2006,344(3),757-764","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.antiviral.2015.09.011","volume":"123","author":"Clark D.N.","year":"2015","unstructured":"Clark D.N.; Hu J.; Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development. Antiviral Res 2015,123,132-137","journal-title":"Antiviral Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11901-010-0039-1","volume":"9","author":"Khungar V.","year":"2010","unstructured":"Khungar V.; Han S.H.; A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B. Curr Hepat Rep 2010,9(2),75-90","journal-title":"Curr Hepat Rep"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1128\/JVI.02575-13","volume":"88","author":"V\u00f6r\u00f6s J.","year":"2014","unstructured":"V\u00f6r\u00f6s J.; Urbanek A.; Rautureau G.J.; Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase. J Virol 2014,88(5),2584-2599","journal-title":"J Virol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.antiviral.2016.06.005","volume":"132","author":"Villa J.A.","year":"2016","unstructured":"Villa J.A.; Pike D.P.; Patel K.B.; Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors. Antiviral Res 2016,132,186-195","journal-title":"Antiviral Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/JVI.03000-13","volume":"88","author":"Hayer J.","year":"2014","unstructured":"Hayer J.; Rodriguez C.; Germanidis G.; Ultradeep pyrosequencing and molecular modeling identify key structural features of hepatitis B virus RNase H, a putative target for antiviral intervention. J Virol 2014,88(1),574-582","journal-title":"J Virol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-4939-6700-1_14","volume":"1540","author":"Lomonosova E.","year":"2017","unstructured":"Lomonosova E.; Tavis J.E.; In vitro enzymatic and cell culture-based assays for measuring activity of HBV RNaseH inhibitors. Methods Mol Biol 2017,1540,179-192","journal-title":"Methods Mol Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.antiviral.2015.04.002","volume":"118","author":"Tavis J.E.","year":"2015","unstructured":"Tavis J.E.; Lomonosova E.; The hepatitis B virus ribonuclease H as a drug target. Antiviral Res 2015,118,132-138","journal-title":"Antiviral Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.antiviral.2013.06.007","volume":"99","author":"Hu Y.","year":"2013","unstructured":"Hu Y.; Cheng X.; Cao F.; Huang A.; Tavis J.E.; \u03b2-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res 2013,99(3),221-229","journal-title":"Antiviral Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.antiviral.2014.05.007","volume":"108","author":"Cai C.W.","year":"2014","unstructured":"Cai C.W.; Lomonosova E.; Moran E.A.; Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antiviral Res 2014,108,48-55","journal-title":"Antiviral Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1128\/AAC.04617-14","volume":"59","author":"Lu G.","year":"2015","unstructured":"Lu G.; Lomonosova E.; Cheng X.; Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrob Agents Chemother 2015,59(2),1070-1079","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1128\/JVI.03058-15","volume":"90","author":"Venkatakrishnan B.","year":"2016","unstructured":"Venkatakrishnan B.; Katen S.P.; Francis S.; Chirapu S.; Finn M.G.; Zlotnick A.; Hepatitis B virus capsids have diverse structural responses to small-molecule ligands bound to the heteroaryldihydropyrimidine pocket. J Virol 2016,90(8),3994-4004","journal-title":"J Virol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/14728222.2017.1397134","volume":"21","author":"Mak L.Y.","year":"2017","unstructured":"Mak L.Y.; Wong D.K.; Seto W.K.; Lai C.L.; Yuen M.F.; Hepatitis B core protein as a therapeutic target. Expert Opin Ther Targets 2017,21(12),1153-1159","journal-title":"Expert Opin Ther Targets"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.peptides.2009.07.006","volume":"30","author":"Zhang W.","year":"2009","unstructured":"Zhang W.; Ke W.; Wu S.S.; An adenovirus-delivered peptide aptamer C1-1 targeting the core protein of hepatitis B virus inhibits viral DNA replication and production in vitro and in vivo. Peptides 2009,30(10),1816-1821","journal-title":"Peptides"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1038\/sj.onc.1204805","volume":"20","author":"Butz K.","year":"2001","unstructured":"Butz K.; Denk C.; Fitscher B.; Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 2001,20(45),6579-6586","journal-title":"Oncogene"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/S1386-6532(05)80026-5","volume":"34","author":"Cheng Y.C.","year":"2005","unstructured":"Cheng Y.C.; Ying C.X.; Leung C.H.; Li Y.; New targets and inhibitors of HBV replication to combat drug resistance. J Clin Virol 2005,34(Suppl. 1),S147-S150","journal-title":"J Clin Virol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bmcl.2009.10.119","volume":"20","author":"Zhu X.","year":"2010","unstructured":"Zhu X.; Zhao G.; Zhou X.; 2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly. Bioorg Med Chem Lett 2010,20(1),299-301","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.bmcl.2014.07.032","volume":"24","author":"Yang X.Y.","year":"2014","unstructured":"Yang X.Y.; Xu X.Q.; Guan H.; A new series of HAPs as anti-HBV agents targeting at capsid assembly. Bioorg Med Chem Lett 2014,24(17),4247-4249","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.bmc.2016.12.017","volume":"25","author":"Ren Q.","year":"2017","unstructured":"Ren Q.; Liu X.; Luo Z.; Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). Bioorg Med Chem 2017,25(3),1042-1056","journal-title":"Bioorg Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/jmr.801","volume":"19","author":"Stray S.J.","year":"2006","unstructured":"Stray S.J.; Zlotnick A.; BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit 2006,19(6),542-548","journal-title":"J Mol Recognit"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.1128\/JVI.00582-13","volume":"87","author":"Campagna M.R.","year":"2013","unstructured":"Campagna M.R.; Liu F.; Mao R.; Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol 2013,87(12),6931-6942","journal-title":"J Virol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1126\/science.1077215","volume":"299","author":"Deres K.","year":"2003","unstructured":"Deres K.; Schr\u00f6der C.H.; Paessens A.; Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003,299(5608),893-896","journal-title":"Science"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.24875\/AIDSRev.M17000012","volume":"20","author":"Soriano V.","year":"2018","unstructured":"Soriano V.; Hot news: Hepatitis B gene therapy coming to age. AIDS Rev 2018,20(2),125-127","journal-title":"AIDS Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/liv.13001","volume":"36","author":"Kumar R.","year":"2016","unstructured":"Kumar R.; P\u00e9rez-Del-Pulgar S.; Testoni B.; Leboss\u00e9 F.; Zoulim F.; Clinical relevance of the study of hepatitis B virus covalently closed circular DNA. Liver Int 2016,36(Suppl. 1),72-77","journal-title":"Liver Int"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","volume":"64","author":"Lucifora J.","year":"2016","unstructured":"Lucifora J.; Protzer U.; Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. J Hepatol 2016,64(1)(Suppl.),S41-S48","journal-title":"J Hepatol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.antiviral.2015.10.004","volume":"123","author":"Kennedy E.M.","year":"2015","unstructured":"Kennedy E.M.; Kornepati A.V.; Cullen B.R.; Targeting hepatitis B virus cccDNA using CRISPR\/Cas9. Antiviral Res 2015,123,188-192","journal-title":"Antiviral Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3e186.","DOI":"10.1038\/mtna.2014.38","author":"Lin SR","year":"2014","unstructured":"Lin SR; Yang HC; Kuo YT; The CRISPR\/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids 2014,3e186."},{"key":"ref=33","author":"Moyo B","year":"2017","unstructured":"Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P.; Advances with using CRISPR\/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res pii: S0168-1702(16)30733-X.2017"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1042\/BJ20140316","volume":"462","author":"Chinnappan M.","year":"2014","unstructured":"Chinnappan M.; Singh A.K.; Kakumani P.K.; Key elements of the RNAi pathway are regulated by hepatitis B virus replication and HBx acts as a viral suppressor of RNA silencing. Biochem J 2014,462(2),347-358","journal-title":"Biochem J"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.bbrc.2003.10.009","volume":"311","author":"Chen Y.","year":"2003","unstructured":"Chen Y.; Du D.; Wu J.; Inhibition of hepatitis B virus replication by stably expressed shRNA. Biochem Biophys Res Commun 2003,311(2),398-404","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.bbrc.2007.01.163","volume":"355","author":"Li G.Q.","year":"2007","unstructured":"Li G.Q.; Gu H.X.; Li D.; Xu W.Z.; Inhibition of Hepatitis B virus cccDNA replication by siRNA. Biochem Biophys Res Commun 2007,355(2),404-408","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12013-014-9847-1","volume":"69","author":"Li G.","year":"2014","unstructured":"Li G.; Jiang G.; Lu J.; Inhibition of hepatitis B virus cccDNA by siRNA in transgenic mice. Cell Biochem Biophys 2014,69(3),649-654","journal-title":"Cell Biochem Biophys"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4149\/av_2012_01_49","volume":"56","author":"Xie Q.","year":"2012","unstructured":"Xie Q.; Zhang S.; Wang W.; Inhibition of hepatitis B virus gene expression by small interfering RNAs targeting cccDNA and X antigen. Acta Virol 2012,56(1),49-55","journal-title":"Acta Virol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2011.05.001","volume":"141","author":"Ebert G.","year":"2011","unstructured":"Ebert G.; Poeck H.; Lucifora J.; 5\u2032-Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology 2011,141(2),696-706","journal-title":"Gastroenterology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/jvh.12479","volume":"23","author":"van de Klundert M.A.","year":"2016","unstructured":"van de Klundert M.A.; Zaaijer H.L.; Kootstra N.A.; Identification of FDA-approved drugs that target hepatitis B virus transcription. J Viral Hepat 2016,23(3),191-201","journal-title":"J Viral Hepat"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.antiviral.2006.01.003","volume":"70","author":"Asif-Ullah M.","year":"2006","unstructured":"Asif-Ullah M.; Choi K.J.; Choi K.I.; Jeong Y.J.; Yu Y.G.; Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus. Antiviral Res 2006,70(2),85-90","journal-title":"Antiviral Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.biopha.2015.02.002","volume":"70","author":"Suresh V.","year":"2015","unstructured":"Suresh V.; Krishnakumar K.A.; Asha V.V.; A new fluorescent based screening system for high throughput screening of drugs targeting HBV-core and HBsAg interaction. Biomed Pharmacother 2015,70,305-316","journal-title":"Biomed Pharmacother"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/aps.2013.175","volume":"35","author":"Yang L.","year":"2014","unstructured":"Yang L.; Shi L.P.; Chen H.J.; Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol Sin 2014,35(3),410-418","journal-title":"Acta Pharmacol Sin"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"9281","DOI":"10.1128\/JVI.00466-15","volume":"89","author":"Orabi A.","year":"2015","unstructured":"Orabi A.; Bieringer M.; Geerlof A.; Bruss V.; An Aptamer against the Matrix Binding Domain on the Hepatitis B Virus Capsid Impairs Virion Formation. J Virol 2015,89(18),9281-9287","journal-title":"J Virol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","volume":"5","author":"Vaillant A.","year":"2019","unstructured":"Vaillant A.; REP 2139: Antiviral mechanisms and applications in achieving functional control of HBV and HDV infection. ACS Infect Dis 2019,5(5),675-687","journal-title":"ACS Infect Dis"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.coviro.2015.07.009","volume":"14","author":"Baumert T.F.","year":"2015","unstructured":"Baumert T.F.; Verrier E.R.; Nassal M.; Chung R.T.; Zeisel M.B.; Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol 2015,14,41-46","journal-title":"Curr Opin Virol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/hep.21112","volume":"43","author":"Engelke M.","year":"2006","unstructured":"Engelke M.; Mills K.; Seitz S.; Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 2006,43(4),750-760","journal-title":"Hepatology"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","volume":"443","author":"Iwamoto M.","year":"2014","unstructured":"Iwamoto M.; Watashi K.; Tsukuda S.; Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun 2014,443(3),808-813","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00424-013-1367-0","volume":"466","author":"Anwer M.S.","year":"2014","unstructured":"Anwer M.S.; Stieger B.; Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch 2014,466(1),77-89","journal-title":"Pflugers Arch"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/gutjnl-2013-304594","volume":"62","author":"Seeger C.","year":"2013","unstructured":"Seeger C.; Mason W.S.; Sodium-dependent taurocholic cotransporting polypeptide: a candidate receptor for human hepatitis B virus. Gut 2013,62(8),1093-1095","journal-title":"Gut"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.antiviral.2015.06.002","volume":"121","author":"Yan H.","year":"2015","unstructured":"Yan H.; Liu Y.; Sui J.; Li W.; NTCP opens the door for hepatitis B virus infection. Antiviral Res 2015,121,24-30","journal-title":"Antiviral Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6700-1_1","volume":"1540","author":"Sun Y.","year":"2017","unstructured":"Sun Y.; Qi Y.; Peng B.; Li W.; NTCP-reconstituted in vitro hbv infection system. Methods Mol Biol 2017,1540,1-14","journal-title":"Methods Mol Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1e00049.","DOI":"10.7554\/eLife.00049","author":"Yan H","year":"2012","unstructured":"Yan H; Zhong G; Xu G; Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus eLife. 2012,1e00049."},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","volume":"146","author":"Ni Y.","year":"2014","unstructured":"Ni Y.; Lempp F.A.; Mehrle S.; Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014,146(4),1070-1083","journal-title":"Gastroenterology"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/j.gastro.2014.02.024","volume":"146","author":"Tong S.","year":"2014","unstructured":"Tong S.; Li J.; Identification of NTCP as an HBV receptor: the beginning of the end or the end of the beginning? Gastroenterology 2014,146(4),902-905","journal-title":"Gastroenterology"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1159\/000371692","volume":"33","author":"Yan H.","year":"2015","unstructured":"Yan H.; Li W.; Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus. Dig Dis 2015,33(3),388-396","journal-title":"Dig Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jhep.2016.02.011","volume":"64","author":"Li W.","year":"2016","unstructured":"Li W.; Urban S.; Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J Hepatol 2016,64(1)(Suppl.),S32-S40","journal-title":"J Hepatol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nbt1389","volume":"26","author":"Petersen J.","year":"2008","unstructured":"Petersen J.; Dandri M.; Mier W.; Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008,26(3),335-341","journal-title":"Nat Biotechnol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.3390\/molecules15074773","volume":"15","author":"Schieck A.","year":"2010","unstructured":"Schieck A.; M\u00fcller T.; Schulze A.; Haberkorn U.; Urban S.; Mier W.; Solid-phase synthesis of the lipopeptide Myr-HBVpreS\/2-78, a hepatitis B virus entry inhibitor. Molecules 2010,15(7),4773-4783","journal-title":"Molecules"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","volume":"65","author":"Blank A.","year":"2016","unstructured":"Blank A.; Markert C.; Hohmann N.; First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 2016,65(3),483-489","journal-title":"J Hepatol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.antiviral.2014.09.009","volume":"111","author":"Huang H.C.","year":"2014","unstructured":"Huang H.C.; Tao M.H.; Hung T.M.; Chen J.C.; Lin Z.J.; Huang C.; (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res 2014,111,100-111","journal-title":"Antiviral Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.26982","volume":"59","author":"Watashi K.","year":"2014","unstructured":"Watashi K.; Sluder A.; Daito T.; Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 2014,59(5),1726-1737","journal-title":"Hepatology"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.compbiolchem.2007.01.005","volume":"31","author":"Jin W.B.","year":"2007","unstructured":"Jin W.B.; Wu F.L.; Kong D.; Guo A.G.; HBV-encoded microRNA candidate and its target. Comput Biol Chem 2007,31(2),124-126","journal-title":"Comput Biol Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1093\/nar\/gkr067","volume":"39","author":"Potenza N.","year":"2011","unstructured":"Potenza N.; Papa U.; Mosca N.; Zerbini F.; Nobile V.; Russo A.; Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res 2011,39(12),5157-5163","journal-title":"Nucleic Acids Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1111\/jvh.12240","volume":"21","author":"Kohno T.","year":"2014","unstructured":"Kohno T.; Tsuge M.; Murakami E.; Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA. J Viral Hepat 2014,21(9),e89-e97","journal-title":"J Viral Hepat"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.antiviral.2010.08.008","volume":"88","author":"Zhang G.L.","year":"2010","unstructured":"Zhang G.L.; Li Y.X.; Zheng S.Q.; Liu M.; Li X.; Tang H.; Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res 2010,88(2),169-175","journal-title":"Antiviral Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"35029","DOI":"10.1074\/jbc.M114.589978","volume":"289","author":"Zhao F.","year":"2014","unstructured":"Zhao F.; Xu G.; Zhou Y.; MicroRNA-26b inhibits hepatitis B virus transcription and replication by targeting the host factor CHORDC1 protein. J Biol Chem 2014,289(50),35029-35041","journal-title":"J Biol Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.bbrc.2010.07.021","volume":"398","author":"Qiu L.","year":"2010","unstructured":"Qiu L.; Fan H.; Jin W.; miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010,398(4),771-777","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1096\/fj.11-187781","volume":"25","author":"Chen Y.","year":"2011","unstructured":"Chen Y.; Shen A.; Rider P.J.; A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 2011,25(12),4511-4521","journal-title":"FASEB J"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hep.24809","volume":"55","author":"Wang S.","year":"2012","unstructured":"Wang S.; Qiu L.; Yan X.; Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology 2012,55(3),730-741","journal-title":"Hepatology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1128\/JVI.02831-12","volume":"87","author":"Li C.","year":"2013","unstructured":"Li C.; Wang Y.; Wang S.; Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol 2013,87(4),2193-2205","journal-title":"J Virol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/ijms17030280","volume":"17","author":"Hayes C.N.","year":"2016","unstructured":"Hayes C.N.; Chayama K.; MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma. Int J Mol Sci 2016,17(3),280","journal-title":"Int J Mol Sci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11262-010-0555-7","volume":"42","author":"Wu F.L.","year":"2011","unstructured":"Wu F.L.; Jin W.B.; Li J.H.; Guo A.G.; Targets for human encoded microRNAs in HBV genes. Virus Genes 2011,42(2),157-161","journal-title":"Virus Genes"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12192-008-0034-4","volume":"13","author":"Bao X.Q.","year":"2008","unstructured":"Bao X.Q.; Liu G.T.; Bicyclol: a novel antihepatitis drug with hepatic heat shock protein 27\/70-inducing activity and cytoprotective effects in mice. Cell Stress Chaperones 2008,13(3),347-355","journal-title":"Cell Stress Chaperones"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1073\/pnas.93.3.1060","volume":"93","author":"Hu J.","year":"1996","unstructured":"Hu J.; Seeger C.; Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci USA 1996,93(3),1060-1064","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"39851","DOI":"10.1074\/jbc.M301618200","volume":"278","author":"Park S.G.","year":"2003","unstructured":"Park S.G.; Lee S.M.; Jung G.; Antisense oligodeoxynucleotides targeted against molecular chaperonin Hsp60 block human hepatitis B virus replication. J Biol Chem 2003,278(41),39851-39857","journal-title":"J Biol Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1073\/pnas.61.2.748","volume":"61","author":"Tenhunen R.","year":"1968","unstructured":"Tenhunen R.; Marver H.S.; Schmid R.; The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968,61(2),748-755","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2007.07.021","volume":"133","author":"Protzer U.","year":"2007","unstructured":"Protzer U.; Seyfried S.; Quasdorff M.; Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology 2007,133(4),1156-1165","journal-title":"Gastroenterology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2893.2005.00611.x","volume":"12","author":"Yang J.","year":"2005","unstructured":"Yang J.; Bo X.C.; Yao J.; Yang N.M.; Wang S.Q.; Differentially expressed cellular genes following HBV: potential targets of anti-HBV drugs? J Viral Hepat 2005,12(4),357-363","journal-title":"J Viral Hepat"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/JVI.69.2.840-848.1995","volume":"69","author":"Budkowska A.","year":"1995","unstructured":"Budkowska A.; Bedossa P.; Groh F.; Louise A.; Pillot J.; Fibronectin of human liver sinusoids binds hepatitis B virus: identification by an anti-idiotypic antibody bearing the internal image of the pre-S2 domain. J Virol 1995,69(2),840-848","journal-title":"J Virol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.bbrc.2014.07.023","volume":"450","author":"Chen Z.","year":"2014","unstructured":"Chen Z.; Zhu M.; Pan X.; Inhibition of Hepatitis B virus replication by SAMHD1. Biochem Biophys Res Commun 2014,450(4),1462-1468","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.virol.2016.05.001","volume":"495","author":"Jeong G.U.","year":"2016","unstructured":"Jeong G.U.; Park I.H.; Ahn K.; Ahn B.Y.; Inhibition of hepatitis B virus replication by a dNTPase-dependent function of the host restriction factor SAMHD1. Virology 2016,495,71-78","journal-title":"Virology"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1128\/AAC.01764-09","volume":"54","author":"Wang Y.P.","year":"2010","unstructured":"Wang Y.P.; Liu F.; He H.W.; Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus. Antimicrob Agents Chemother 2010,54(5),2070-2077","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4732","DOI":"10.1016\/j.bmcl.2011.06.071","volume":"21","author":"Du N.N.","year":"2011","unstructured":"Du N.N.; Li X.; Wang Y.P.; Synthesis, structure-activity relationship and biological evaluation of novel N-substituted matrinic acid derivatives as host heat-stress cognate 70 (Hsc70) down-regulators. Bioorg Med Chem Lett 2011,21(16),4732-4735","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"8526","DOI":"10.1073\/pnas.0609883104","volume":"104","author":"Ying C.","year":"2007","unstructured":"Ying C.; Li Y.; Leung C.H.; Robek M.D.; Cheng Y.C.; Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci USA 2007,104(20),8526-8531","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/35093050","volume":"413","author":"Yoon J.C.","year":"2001","unstructured":"Yoon J.C.; Puigserver P.; Chen G.; Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001,413(6852),131-138","journal-title":"Nature"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"16003","DOI":"10.1073\/pnas.0607837103","volume":"103","author":"Shlomai A.","year":"2006","unstructured":"Shlomai A.; Paran N.; Shaul Y.; PGC-1alpha controls hepatitis B virus through nutritional signals. Proc Natl Acad Sci USA 2006,103(43),16003-16008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.bbrc.2009.02.078","volume":"381","author":"Shlomai A.","year":"2009","unstructured":"Shlomai A.; Shaul Y.; The metabolic activator FOXO1 binds hepatitis B virus DNA and activates its transcription. Biochem Biophys Res Commun 2009,381(4),544-548","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mehy.2007.08.032","volume":"71","author":"Shlomai A.","year":"2008","unstructured":"Shlomai A.; Shaul Y.; The \u201cmetabolovirus\u201d model of hepatitis B virus suggests nutritional therapy as an effective anti-viral weapon. Med Hypotheses 2008,71(1),53-57","journal-title":"Med Hypotheses"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.febslet.2010.04.067","volume":"584","author":"Rechtman M.M.","year":"2010","unstructured":"Rechtman M.M.; Har-Noy O.; Bar-Yishay I.; Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha. FEBS Lett 2010,584(11),2485-2490","journal-title":"FEBS Lett"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1128\/JVI.02861-13","volume":"88","author":"Ren J.H.","year":"2014","unstructured":"Ren J.H.; Tao Y.; Zhang Z.Z.; Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1. J Virol 2014,88(5),2442-2451","journal-title":"J Virol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1365-2893.2005.00666.x","volume":"13","author":"Yang J.","year":"2006","unstructured":"Yang J.; Bo X.C.; Ding X.R.; Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication. J Viral Hepat 2006,13(3),158-165","journal-title":"J Viral Hepat"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/hep.23519","volume":"51","author":"Cohen D.","year":"2010","unstructured":"Cohen D.; Adamovich Y.; Reuven N.; Shaul Y.; Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. Hepatology 2010,51(5),1538-1546","journal-title":"Hepatology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"Lucifora J.","year":"2014","unstructured":"Lucifora J.; Xia Y.; Reisinger F.; Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014,343(6176),1221-1228","journal-title":"Science"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"17176","DOI":"10.1073\/pnas.1009445107","volume":"107","author":"Pollock S.","year":"2010","unstructured":"Pollock S.; Nichita N.B.; B\u00f6hmer A.; Radulescu C.; Dwek R.A.; Zitzmann N.; Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc Natl Acad Sci USA 2010,107(40),17176-17181","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1038\/srep08421","volume":"5","author":"Li H.","year":"2015","unstructured":"Li H.; Zhu W.; Zhang L.; The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment. Sci Rep 2015,5,8421","journal-title":"Sci Rep"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbrc.2016.05.043","volume":"475","author":"Okamura H.","year":"2016","unstructured":"Okamura H.; Nio Y.; Akahori Y.; Fatty acid biosynthesis is involved in the production of hepatitis B virus particles. Biochem Biophys Res Commun 2016,475(1),87-92","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bcp.2016.01.003","volume":"103","author":"Liu X.","year":"2016","unstructured":"Liu X.; Xu Z.; Hou C.; Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein. Biochem Pharmacol 2016,103,118-128","journal-title":"Biochem Pharmacol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12985-015-0245-0","volume":"12","author":"Chen E.Q.","year":"2015","unstructured":"Chen E.Q.; Dai J.; Bai L.; Tang H.; The efficacy of zinc finger antiviral protein against hepatitis B virus transcription and replication in tansgenic mouse model. Virol J 2015,12,25","journal-title":"Virol J"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.4155\/fmc-2017-0089","volume":"9","author":"Richters A.","year":"2017","unstructured":"Richters A.; Targeting protein arginine methyltransferase 5 in disease. Future Med Chem 2017,9(17),2081-2098","journal-title":"Future Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186982","volume":"12","author":"Lubyova B.","year":"2017","unstructured":"Lubyova B.; Hodek J.; Zabransky A.; PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core. PLoS One 2017,12(10)","journal-title":"PLoS One"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/hep.29133","volume":"66","author":"Zhang W.","year":"2017","unstructured":"Zhang W.; Chen J.; Wu M.; PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology 2017,66(2),398-415","journal-title":"Hepatology"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1128\/JVI.02574-12","volume":"87","author":"Benhenda S.","year":"2013","unstructured":"Benhenda S.; Ducroux A.; Rivi\u00e8re L.; Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol 2013,87(8),4360-4371","journal-title":"J Virol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.bbrc.2018.04.187","volume":"501","author":"Saso W.","year":"2018","unstructured":"Saso W.; Tsukuda S.; Ohashi H.; A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction. Biochem Biophys Res Commun 2018,501(2),374-379","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/hep.25608","volume":"56","author":"Li N.","year":"2012","unstructured":"Li N.; Zhang L.; Chen L.; MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen. Hepatology 2012,56(3),803-811","journal-title":"Hepatology"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"A83","DOI":"10.1016\/S0264-410X(02)00393-6","volume":"20","author":"Michel M.L.","year":"2002","unstructured":"Michel M.L.; Towards immunotherapy for chronic hepatitis B virus infections. Vaccine 2002,20(Suppl. 4),A83-A88","journal-title":"Vaccine"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1042\/CS20120169","volume":"124","author":"Grimm D.","year":"2013","unstructured":"Grimm D.; Heeg M.; Thimme R.; Hepatitis B virus: from immunobiology to immunotherapy. Clin Sci (Lond) 2013,124(2),77-85","journal-title":"Clin Sci (Lond)"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1016\/j.febslet.2013.08.044","volume":"587","author":"Liu D.","year":"2013","unstructured":"Liu D.; Ni B.; Wang L.; Zhang M.; Liu W.; Wu Y.; Hepatitis B virus core protein interacts with CD59 to promote complement-mediated liver inflammation during chronic hepatitis B virus infection. FEBS Lett 2013,587(20),3314-3320","journal-title":"FEBS Lett"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1016\/j.vaccine.2011.05.008","volume":"29","author":"Wang S.","year":"2011","unstructured":"Wang S.; Qiu L.; Liu G.; Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB\/c and transgenic mice. Vaccine 2011,29(37),6342-6351","journal-title":"Vaccine"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0140-6736(00)04050-2","volume":"357","author":"Meng S.D.","year":"2001","unstructured":"Meng S.D.; Gao T.; Gao G.F.; Tien P.; HBV-specific peptide associated with heat-shock protein gp96. Lancet 2001,357(9255),528-529","journal-title":"Lancet"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1002\/eji.200939593","volume":"39","author":"Liu Z.","year":"2009","unstructured":"Liu Z.; Li X.; Qiu L.; Treg suppress CTL responses upon immunization with HSP gp96. Eur J Immunol 2009,39(11),3110-3120","journal-title":"Eur J Immunol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/postgradmedj-2013-132309","volume":"90","author":"Shahrakyvahed A.","year":"2014","unstructured":"Shahrakyvahed A.; Sanchooli J.; Sanadgol N.; Arababadi M.K.; Kennedy D.; TLR9: an important molecule in the fight against hepatitis B virus. Postgrad Med J 2014,90(1065),396-401","journal-title":"Postgrad Med J"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.3748\/wjg.v11.i42.6631","volume":"11","author":"Chang W.W.","year":"2005","unstructured":"Chang W.W.; Su I.J.; Lai M.D.; Chang W.T.; Huang W.; Lei H.Y.; Toll-like receptor 4 plays an anti-HBV role in a murine model of acute hepatitis B virus expression. World J Gastroenterol 2005,11(42),6631-6637","journal-title":"World J Gastroenterol"},{"key":"ref=114","first-page":"1508","volume":"144","author":"Lanford RE","year":"2013","unstructured":"Lanford RE; Guerra B; Chavez D; GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 1517.e1-102013,144(7),1508-17"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3748\/wjg.v22.i7.2294","volume":"22","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Gao L.F.; Liang X.H.; Ma C.H.; Role of Tim-3 in hepatitis B virus infection: An overview. World J Gastroenterol 2016,22(7),2294-2303","journal-title":"World J Gastroenterol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00705-013-1965-3","volume":"159","author":"Shabani Z.","year":"2014","unstructured":"Shabani Z.; Bagheri M.; Zare-Bidaki M.; NK cells in hepatitis B virus infection: a potent target for immunotherapy. Arch Virol 2014,159(7),1555-1565","journal-title":"Arch Virol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.bjid.2015.05.006","volume":"19","author":"Wu S.F.","year":"2015","unstructured":"Wu S.F.; Wang W.J.; Gao Y.Q.; Natural killer cells in hepatitis B virus infection. Braz J Infect Dis 2015,19(4),417-425","journal-title":"Braz J Infect Dis"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00535-016-1183-3","volume":"51","author":"Yoshio S.","year":"2016","unstructured":"Yoshio S.; Kanto T.; Host-virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol 2016,51(5),409-420","journal-title":"J Gastroenterol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1751-2980.12218","volume":"16","author":"Xiang X.G.","year":"2015","unstructured":"Xiang X.G.; Xie Q.; IL-35: a potential therapeutic target for controlling hepatitis B virus infection. J Dig Dis 2015,16(1),1-6","journal-title":"J Dig Dis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12016-014-8465-4","volume":"50","author":"Li X.","year":"2016","unstructured":"Li X.; Liu X.; Tian L.; Chen Y.; Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections. Clin Rev Allergy Immunol 2016,50(1),41-54","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.3390\/v9010018","volume":"9","author":"Xia Y.","year":"2017","unstructured":"Xia Y.; Protzer U.; Control of Hepatitis B Virus by Cytokines. Viruses 2017,9(1)","journal-title":"Viruses"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1159\/000430386","volume":"37","author":"Xia C.","year":"2015","unstructured":"Xia C.; Liu Y.; Chen Z.; Zheng M.; Involvement of interleukin 6 in hepatitis B viral infection. Cell Physiol Biochem 2015,37(2),677-686","journal-title":"Cell Physiol Biochem"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/apt.13694","volume":"44","author":"Lin C.L.","year":"2016","unstructured":"Lin C.L.; Kao J.H.; Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther 2016,44(3),213-222","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.1093\/cid\/ciw044","volume":"62","author":"Wilson E.M.","year":"2016","unstructured":"Wilson E.M.; Tang L.; Kottilil S.; Eradication strategies for chronic hepatitis B infection. Clin Infect Dis 2016,62(Suppl. 4),S318-S325","journal-title":"Clin Infect Dis"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.tim.2016.05.006","volume":"24","author":"Shih C.","year":"2016","unstructured":"Shih C.; Chou S.F.; Yang C.C.; Huang J.Y.; Choijilsuren G.; Jhou R.S.; Control and eradication strategies of hepatitis B virus. Trends Microbiol 2016,24(9),739-749","journal-title":"Trends Microbiol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.bpg.2015.09.011","volume":"29","author":"Kao J.H.","year":"2015","unstructured":"Kao J.H.; Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2015,29(6),907-917","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"13293","DOI":"10.3748\/wjg.v20.i37.13293","volume":"20","author":"You C.R.","year":"2014","unstructured":"You C.R.; Lee S.W.; Jang J.W.; Yoon S.K.; Update on hepatitis B virus infection. World J Gastroenterol 2014,20(37),13293-13305","journal-title":"World J Gastroenterol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.antiviral.2010.12.004","volume":"89","author":"Zheng Z.","year":"2011","unstructured":"Zheng Z.; Li J.; Sun J.; Inhibition of HBV replication by theophylline. Antiviral Res 2011,89(2),149-155","journal-title":"Antiviral Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12072-014-9571-3","volume":"9","author":"van Campenhout M.J.","year":"2015","unstructured":"van Campenhout M.J.; Janssen H.L.; How to achieve immune control in chronic hepatitis B? Hepatol Int 2015,9(1),9-16","journal-title":"Hepatol Int"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T06:35:51Z","timestamp":1610692551000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173915\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":129,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,11,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666190729115646","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}